139 related articles for article (PubMed ID: 24346057)
1. Mycophenolate mofetil in liver transplantation: a review.
Kaltenborn A; Schrem H
Ann Transplant; 2013 Dec; 18():685-96. PubMed ID: 24346057
[TBL] [Abstract][Full Text] [Related]
2. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection.
Simmons WD; Rayhill SC; Sollinger HW
Drug Saf; 1997 Aug; 17(2):75-92. PubMed ID: 9285199
[TBL] [Abstract][Full Text] [Related]
3. The use of mycophenolate mofetil in liver transplant recipients.
Detry O; de Roover A; Delwaide J; Meurisse M; Honoré P
Expert Opin Pharmacother; 2003 Nov; 4(11):1949-57. PubMed ID: 14596648
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal side effects in liver transplant recipients taking enteric-coated mycophenolate sodium vs. mycophenolate mofetil.
Lopez-Solis R; DeVera M; Steel J; Fedorek S; Sturdevant M; Hughes C; Humar A
Clin Transplant; 2014 Jul; 28(7):783-8. PubMed ID: 24754682
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil: a unique immunosuppressive agent.
Hood KA; Zarembski DG
Am J Health Syst Pharm; 1997 Feb; 54(3):285-94. PubMed ID: 9028422
[TBL] [Abstract][Full Text] [Related]
6. Clinical evolution in the first 3 months of patients after liver transplantation in maintenance phase converted from mycophenolate mofetil to mycophenolate sodium due to gastrointestinal complications.
Miras M; Carballo F; Egea J; Martínez C; Alvarez-López MR; Sánchez-Bueno F; Parrilla P
Transplant Proc; 2007 Sep; 39(7):2314-7. PubMed ID: 17889175
[TBL] [Abstract][Full Text] [Related]
7. Conversion from Calcineurin Inhibitor-Based Immunosuppression to Mycophenolate Mofetil in Monotherapy Reduces Risk of De Novo Malignancies After Liver Transplantation.
Aguiar D; Martínez-Urbistondo D; D'Avola D; Iñarrairaegui M; Pardo F; Rotellar F; Sangro B; Quiroga J; Herrero JI
Ann Transplant; 2017 Mar; 22():141-147. PubMed ID: 28302995
[TBL] [Abstract][Full Text] [Related]
8. Two case reports of successful withdrawal of mycofenolate mofetil after living donor lobar lung transplantation.
Miyazaki T; Tagawa T; Yamasaki N; Tsuchiya T; Matsumoto K; Nagayasu T
Transplant Proc; 2013; 45(1):356-9. PubMed ID: 23375323
[TBL] [Abstract][Full Text] [Related]
9. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
Flechner SM; Kobashigawa J; Klintmalm G
Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil in liver transplantation--is monotherapy safe?
Schmeding M; Neumann UP; Neuhaus R; Neuhaus P
Clin Transplant; 2006; 20 Suppl 17():75-9. PubMed ID: 17100705
[TBL] [Abstract][Full Text] [Related]
11. Enteric-coated mycophenolate sodium: one-way conversion from mycophenolate mofetil and de novo use in stable liver transplant recipients.
Nure E; Magalini SC; Frongillo F; Barbarino R; Pepe G; Avolio AW; Agnes S
Transplant Proc; 2009 May; 41(4):1290-2. PubMed ID: 19460541
[TBL] [Abstract][Full Text] [Related]
12. Successful conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic) in liver transplant patients with gastrointestinal side effects.
Robaeys G; Cassiman D; Verslype C; Monbaliu D; Aerts R; Pirenne J; Nevens F
Transplant Proc; 2009 Mar; 41(2):610-3. PubMed ID: 19328938
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial.
Yoshida EM; Marotta PJ; Greig PD; Kneteman NM; Marleau D; Cantarovich M; Peltekian KM; Lilly LB; Scudamore CH; Bain VG; Wall WJ; Roy A; Balshaw RF; Barkun JS
Liver Transpl; 2005 Sep; 11(9):1064-72. PubMed ID: 16123958
[TBL] [Abstract][Full Text] [Related]
14. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience.
Kirklin JK; Bourge RC; Naftel DC; Morrow WR; Deierhoi MH; Kauffman RS; White-Williams C; Nomberg RI; Holman WL; Smith DC
J Heart Lung Transplant; 1994; 13(3):444-50. PubMed ID: 8061021
[TBL] [Abstract][Full Text] [Related]
15. Therapy of rheumatoid arthritis with mycophenolate mofetil.
Goldblum R
Clin Exp Rheumatol; 1993; 11 Suppl 8():S117-9. PubMed ID: 8324935
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients.
Cattaneo D; Cortinovis M; Baldelli S; Bitto A; Gotti E; Remuzzi G; Perico N
Clin J Am Soc Nephrol; 2007 Nov; 2(6):1147-55. PubMed ID: 17928466
[TBL] [Abstract][Full Text] [Related]
17. Use of mycophenolate mofetil in liver transplantation: a literature review.
Manzia TM; De Liguori Carino N; Orlando G; Toti L; De Luca L; D'Andria D; Cardillo A; Anselmo A; Casciani CU; Tisone G
Transplant Proc; 2005; 37(6):2616-7. PubMed ID: 16182764
[TBL] [Abstract][Full Text] [Related]
18. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil.
Sánchez Fructuoso A; Calvo N; Moreno MA; Giorgi M; Conesa J; Barrientos A
Transplant Proc; 2007 Sep; 39(7):2194-6. PubMed ID: 17889135
[TBL] [Abstract][Full Text] [Related]
19. [Mycophenolate mofetil, a possible new immunosuppresant].
Weberová J; Voboril R; Semecký V
Ceska Slov Farm; 2002 Sep; 51(5):220-5. PubMed ID: 12407919
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]